Updated:
HITE Hedge Asset Management LLC
HITE Hedge Asset Management, founded by John J. Hite in 2010, invests exclusively in healthcare across public equities and private deals.
HITE Hedge Asset Management LLC
John J. Hite established HITE Hedge Asset Management in 2010, departing from the generalist hedge fund model to concentrate on healthcare. The firm operates from New York City and has remained an independent, healthcare-dedicated investment platform. Wealth origin is not publicly attributed to a single family or endowment, distinguishing it from single-family-office peers. HITE's strategy spans public equities, private placements, PIPEs (private investments in public equity), and structured financing in healthcare. Recorded positions include investments in AveXis (acquired by Novartis in 2018 for $8.7B, per Bloomberg, 2018) and Mirati Therapeutics (acquired by Bristol Myers Squibb in 2023, per Reuters, 2023). The firm's coverage extends to biopharmaceuticals, medical devices, diagnostics, and healthcare services, with a primary geographic focus on North America and selective European opportunities. The firm's team size and AUM have not been publicly disclosed. No additional offices or adjacent philanthropic vehicles have been identified in the public record. HITE's consistent healthcare-only mandate over more than a decade constitutes an operational track record rather than a fund-by-fund pivot. HITE's structural differentiator is its healthcare-only mandate, maintained through market cycles since 2010. This specialization stands in contrast to most hedge funds that rotate across sectors. The firm's willingness to engage in private deals and structured investments alongside public positions gives it flexibility uncommon among pure healthcare funds.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
John J. Hite
Chief Executive Officer & Chief Investment Officer
Sector focus
Frequently asked questions
Who runs investment decisions at HITE Hedge Asset Management?
John J. Hite serves as CEO and CIO, overseeing all investment decisions. He founded the firm in 2010. Public filings show Hite as the lead portfolio manager for the firm's disclosed positions.
Is HITE Hedge Asset Management structured as a family office or a hedge fund?
HITE registers as an asset manager operating like a hedge fund with a healthcare-dedicated mandate. It does not present itself as a family office. The firm's ownership structure is not publicly disclosed, but it operates independently from any single family or endowment.
What types of healthcare investments does HITE pursue?
The firm invests across public equities, private placements, PIPEs, and structured financing. Recorded holdings span biopharmaceuticals, medical devices, and diagnostics. Examples include positions in AveXis (acquired by Novartis in 2018) and Mirati Therapeutics (acquired by Bristol Myers Squibb in 2023).
Does HITE participate in fund commitments or only direct deals?
HITE primarily makes direct stock and structured investments rather than committing to external funds. The firm's model involves placing capital directly into healthcare companies, both public and private, rather than acting as a fund of funds.
What is HITE's known posture on co-investments alongside external GPs?
HITE's involvement in PIPE deals and private placements suggests it can co-invest alongside specialist healthcare funds and venture capital firms, though its specific co-investment posture is not detailed in the public record.
Which sectors does HITE explicitly avoid?
HITE explicitly avoids all sectors outside healthcare. The firm's website and public communications describe it as a healthcare-dedicated manager, passing on technology, energy, consumer, and other non-biomedical opportunities.
What is the longevity of HITE's mandate?
HITE has maintained its healthcare-only mandate since its founding in 2010 — over 14 years. This consistent focus through multiple market cycles, including the COVID-19 pandemic and the 2020–2023 biotech bear market, provides a track record of discipline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: